A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx

Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7. doi: 10.1001/archotol.1996.01890200043010.

Abstract

Objective: To pilot a targeted chemoradiation protocol for patients with advanced carcinoma of the larynx and pharynx that would circumvent upper aerodigestive tract dysfunction related to major oncologic surgery.

Design: Weekly intra-arterial infusions of supradose cisplatin (150 mg/m2 per week x 4) rapidly delivered to the tumor bulk, simultaneous intravenous sodium thiosulfate for systemic drug neutralization, and conventional external-beam irradiation (1.80-2.00 Gy per fraction x 35) were used. Between February 1991 and April 1994, 42 patients were treated who would otherwise have required a major resection of the tongue base, pharyngeal wall, or larynx.

Main outcome measures: Tumor response, toxic effects, disease control above the clavicle, preservation of the larynx, maintenance of oral nutrition, and overall and disease-related 2-year survival.

Results: Three complications were related to the weekly transfemoral superselective intra-arterial procedures performed 160 times. Grade 3 to 4 chemotoxic effects were infrequent, occurring in 9 (5.5%) of 160 cycles, and only 1 patient required a radiotherapy break because of severe mucositis. A complete response in the primary site was obtained in 36 (86%) of 42 patients, 2 of whom had residual disease in the neck. Median follow-up was 13 months (range, 3-46 months). To date, there have been 5 recurrences: 2 regional and 3 distant. The 2-year overall and disease-related survival was 64% and 76%, respectively. The rate of disease control above the clavicle at 2 years was 86%.

Conclusions: We believe this chemoradiation protocol represents an effective management scheme for patients with advanced head and neck cancer while minimizing dysfunction and possibly improving survival.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antidotes / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / therapy*
  • Chemotherapy, Cancer, Regional Perfusion
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Combined Modality Therapy
  • Female
  • Humans
  • Infusions, Intra-Arterial
  • Laryngeal Neoplasms / drug therapy
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / radiotherapy
  • Laryngeal Neoplasms / therapy*
  • Male
  • Middle Aged
  • Pharyngeal Neoplasms / drug therapy
  • Pharyngeal Neoplasms / mortality
  • Pharyngeal Neoplasms / radiotherapy
  • Pharyngeal Neoplasms / therapy*
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiation-Sensitizing Agents / adverse effects
  • Radiotherapy / adverse effects
  • Radiotherapy Dosage
  • Survival Rate
  • Thiosulfates / administration & dosage

Substances

  • Antidotes
  • Antineoplastic Agents
  • Radiation-Sensitizing Agents
  • Thiosulfates
  • sodium thiosulfate
  • Cisplatin